Table III.
PFS and OS of different primary tumors.
| PFS, months | OS, months | |||||||
|---|---|---|---|---|---|---|---|---|
| Primary | Median | 6 | 12 | 18 | Median | 1 | 2 | 3 |
| CRC | 18 | 100.0 | 72.9 | 48.6 | 38 | 92.0 | 75.3 | 28.8 |
| HCC | 6 | 20.0 | – | – | 9 | 20.0 | – | – |
| LC | 16 | 83.9 | 71.9 | 24.0 | 33 | 91.7 | 66.7 | – |
| GCC | 7 | 33.3 | – | – | 12 | 33.3 | – | – |
| STC | 8 | 42.9 | – | – | 15 | 57.1 | – | – |
| RCC | 5 | – | – | – | 13 | 50.0 | – | – |
| EC | 8 | 57.1 | – | – | 12 | 42.9 | – | – |
| GC | 17 | – | – | – | 17 | – | – | – |
| BC | 15 | 100.0 | 66.7 | – | 26 | 50.0 | – | – |
| All patients | 14 | 82.1 | 55.7 | 27.5 | 24 | 83.6 | 46.3 | 14.3 |
PFS, progression-free survival; OS, overall survival; CRC, colorectal cancer; HCC, hepatocarcinoma; LC, local control; GCC, gynecological cancer; STC, soft tissue sarcoma; RCC, renal cellcarcinoma; EC, esophagus carcinoma; GC, gastric carcinoma; BC, breast cancer.